Genialis

Genialis is a precision oncology company dedicated to helping the most promising drug molecules become life-saving medicines. Operating at the intersection of advanced artificial intelligence and deep biological expertise, Genialis addresses two of the most critical challenges in oncology: the fact that most cancer patients do not benefit from the medicines they receive, and that most molecules fail in clinical trials. The company serves pharmaceutical and biotech organizations across the entire drug development lifecycle, providing therapeutic intelligence to improve patient outcomes and clinical success rates.

Genialis tackles these problems by building what it describes as the most accurate and informative AI models of cancer biology. The company helps drug developers answer fundamental questions — why some patients improve while others worsen, what a molecule's mechanism of action truly is, how resistance develops, which indications hold the greatest promise, and whether patient stratification strategies could enhance clinical success. Genialis has offices in Houston, Ljubljana, and Boston, and is a founding member of the Alliance for AI in Healthcare.

Core Technology Platform

• Genialis™ Supermodel: An AI foundation model of cancer biology, designed to deliver the most accurate and informative representations of cancer for drug development and patient stratification purposes.
• Genialis Expressions: A multiomics and clinical data infrastructure platform that underpins the company's analytical capabilities, enabling integration and analysis of complex biological and clinical datasets.

Approach and Capabilities

• Genialis provides therapeutic intelligence across the entire drug development lifecycle, from early discovery through clinical development.
• The company applies true precision medicine principles, combining advanced AI modeling with deep domain expertise in cancer biology.
• Key analytical capabilities include understanding mechanisms of action, identifying and characterizing drug resistance, defining patient populations most likely to respond, and guiding indication selection.
• Patient stratification strategies are a central focus, helping sponsors design more targeted and successful clinical trials.

Case Studies and Applications

• Genialis™ krasID: A case study focused on KRAS biology, with research presented at the RAS Summit 2024 and AACR 2025, demonstrating the platform's ability to characterize one of oncology's most challenging mutation targets.
• DNA Damage Response (DDR) Biomarker: A case study exploring DDR biomarker identification and application, with research also presented at AACR 2025, illustrating the platform's breadth across different oncology mechanisms.
• Research findings have been shared at major scientific conferences including ASCO 2025 and AACR 2025, reflecting the company's active engagement with the scientific community.

Partnerships, Media, and Community

• Genialis works with featured partners across the pharmaceutical and biotech industry, supporting collaborative drug development efforts.
• The company hosts the TPM Podcast, which covers topics such as pre-competitive collaboration, data sharing, and AI in oncology, featuring guests such as Sean Khozin discussing how these efforts advance cancer research and innovation.
• Genialis publishes scientific publications and press releases, and participates in industry news and events to disseminate its research findings.
• As a founding member of the Alliance for AI in Healthcare, Genialis is committed to responsible and impactful application of AI in the healthcare sector.

With a mission centered on knowing the patient and knowing the drug, Genialis brings together AI-driven biological modeling and clinical data infrastructure to transform how oncology therapeutics are developed and matched to the patients most likely to benefit.